Mirati Therapeutics, Inc. (MRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 58.46 |
| Open | 40.28 |
| Bid | 39.20 x 800 |
| Ask | 39.69 x 800 |
| Day's Range | 32.96 - 40.51 |
| 52 Week Range | 32.96 - 195.99 |
| Volume | |
| Avg. Volume | 887,217 |
| Market Cap | 2.211B |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.96 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 137.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Related Research
- Mirati Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- Investor's Business Daily
Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
- Zacks
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
- MarketWatch
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
